Johnson & Johnson (JNJ) transition underway, UBS assesses upcoming analyst day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors
November 30, 2023 4:30 PM ESTNEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) announced today that Eugene A. Woods, MBA, MHA, Chief Executive Officer of Advocate Health, has been appointed to its Board of Directors.
Mr. Woods is an exceptional addition to Johnson & Johnsons Board of Directors, said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. Mr. Woods has an impressive career of leading and transforming healthcare systems while prioritizing the delivery of high-quality, equitable patient care. The Board looks forward to working with him as the Company continues to focus on healthcare... More
Johnson & Johnson MedTech Acquires Laminar, Inc.
November 30, 2023 8:40 AM ESTInnovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation
Strengthens position in high-growth MedTech segments
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to customary adjustments, with additional potential clinical and regulatory... More
